• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 5. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952

Recent Advances in the Study of 4-Pyridinemethanol, α-(2-aminoethyl)-3-bromo- (CAS: 1782495-28-6)

The compound 4-Pyridinemethanol, α-(2-aminoethyl)-3-bromo- (CAS: 1782495-28-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic potential.

Recent studies have highlighted the unique structural features of 4-Pyridinemethanol, α-(2-aminoethyl)-3-bromo-, which make it a promising candidate for targeting specific biological pathways. The presence of the bromo-substituent at the 3-position and the aminoethyl side chain at the α-position of the pyridine ring contribute to its ability to interact with various enzymes and receptors. Researchers have employed advanced synthetic techniques, including multi-step organic synthesis and catalysis, to optimize the production of this compound with high purity and yield.

In vitro and in vivo studies have demonstrated the compound's efficacy in modulating key cellular processes. For instance, it has shown inhibitory activity against certain kinases involved in inflammatory and oncogenic pathways. These findings suggest potential applications in the treatment of diseases such as cancer and autoimmune disorders. Additionally, the compound's ability to cross the blood-brain barrier has sparked interest in its use for neurological conditions.

Further investigations into the mechanism of action of 4-Pyridinemethanol, α-(2-aminoethyl)-3-bromo- have revealed its role in disrupting protein-protein interactions critical for disease progression. Structural-activity relationship (SAR) studies are ongoing to identify derivatives with enhanced potency and selectivity. Collaborative efforts between academic institutions and pharmaceutical companies are accelerating the translation of these discoveries into preclinical candidates.

In conclusion, the compound 4-Pyridinemethanol, α-(2-aminoethyl)-3-bromo- (CAS: 1782495-28-6) represents a promising scaffold for the development of novel therapeutics. Continued research into its biological properties and optimization of its chemical structure will be essential for realizing its full potential in medicine. Future studies should focus on addressing challenges related to pharmacokinetics and toxicity to facilitate its progression into clinical trials.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)